SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.5 HKD | +0.43% |
|
+0.54% | +32.90% |
| May. 16 | Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong | CI |
| Apr. 18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
| Sales 2024 * | 3.61B 499M 3.9B | Sales 2025 * | 4.09B 564M 4.41B | Capitalization | 10.39B 1.43B 11.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.15B 159M 1.24B | Net income 2025 * | 1.23B 170M 1.33B | EV / Sales 2024 * | 2.16 x |
| Net cash position 2024 * | 2.6B 358M 2.8B | Net cash position 2025 * | 3.51B 485M 3.79B | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
9.68
x | P/E ratio 2025 * |
9.02
x | Employees | 1,050 |
| Yield 2024 * |
1.28% | Yield 2025 * |
-
| Free-Float | 52.65% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.43% | ||
| 1 week | +0.54% | ||
| 1 month | +3.12% | ||
| 3 months | +42.09% | ||
| 6 months | +36.03% | ||
| Current year | +32.90% |
1 week
18.30
18.52
1 month
17.9618.52
Current year
10.2618.52
1 year
8.7518.52
3 years
5.6518.52
5 years
5.6519.38
10 years
5.6519.38
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Zhao
CEO | Chief Executive Officer | 60 | 20-05-31 |
Rong Rong Pan
DFI | Director of Finance/CFO | 46 | - |
Mao Li
CTO | Chief Tech/Sci/R&D Officer | 66 | 22-06-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Vasella
BRD | Director/Board Member | 70 | 20-05-31 |
Hong Zhao
CEO | Chief Executive Officer | 60 | 20-05-31 |
Zhen Fu Li
CHM | Chairman | 59 | 20-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 4 M€ | -27.92% | ||
| 0.05% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 18.5 | +0.43% | 4,546,456 |
| 24-05-30 | 18.42 | +0.55% | 2,296,500 |
| 24-05-29 | 18.32 | -0.54% | 5,744,038 |
| 24-05-28 | 18.42 | -0.11% | 3,156,000 |
| 24-05-27 | 18.44 | +0.22% | 2,307,497 |
Delayed Quote Hong Kong S.E., May 31, 2024 at 04:08 am EDT
More quotes
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
17.13
CNY
Average target price
16.5
CNY
Spread / Average Target
-3.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +32.90% | 1.43B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- 6600 Stock
